UPDATE 1-India to ship COVID-19 vaccines to Canada as diplomatic tension eases

Published 2021-02-15, 07:23 a/m

(Adds details)

BENGALURU, Feb 15 (Reuters) - India's Serum Institute will ship COVID-19 vaccines to Canada within a month, its chief executive said on Monday, in a sign a diplomatic row triggered by Canadian Prime Minister Justin Trudeau's comments on political protests in India was easing.

Trudeau said the months-long protests by farmers on the outskirts of Delhi were concerning, drawing a rebuke from the Indian government which said it was an internal matter.

Last week, however, Trudeau spoke to Indian counterpart Narendra Modi and they discussed the two countries' commitment to democracy.

Modi also said India would do its best to supply COVID-19 vaccines sought by Canada. Monday Adar Poonawalla, the chief executive of Serum Institute of India (SII) - the world's largest vaccine maker - reaffirmed that commitment.

"As we await regulatory approvals from Canada, I assure you, @SerumInstIndia will fly out #COVISHIELD to Canada in less than a month; I'm on it!" Poonawalla said in a Tweet, using the brand name under which Serum produces the shot developed by Oxford University and AstraZeneca (NASDAQ:AZN) Plc AZN.L .

India's SII has emerged as a key vaccine supplier amid the pandemic. Canada, like many other countries, is relying on foreign supplies because it is unable to produce the vaccine locally.

Experts and officials say India has been trying to use its vaccine dominance to shore up diplomatic support.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.